- Home
- JAZZ vs QRVO Comparison
JAZZ vs QRVO Comparison
Compare JAZZ & QRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAZZ
- QRVO
- Stock Information
- Founded
- JAZZ 2003
- QRVO 1957
- Country
- JAZZ Ireland
- QRVO United States
- Employees
- JAZZ N/A
- QRVO N/A
- Industry
- JAZZ Biotechnology: Pharmaceutical Preparations
- QRVO Semiconductors
- Sector
- JAZZ Health Care
- QRVO Technology
- Exchange
- JAZZ Nasdaq
- QRVO Nasdaq
- Market Cap
- JAZZ 6.1B
- QRVO 6.0B
- IPO Year
- JAZZ 2007
- QRVO 1997
- Fundamental
- Price
- JAZZ $97.78
- QRVO $73.19
- Analyst Decision
- JAZZ Strong Buy
- QRVO Hold
- Analyst Count
- JAZZ 13
- QRVO 19
- Target Price
- JAZZ $181.85
- QRVO $89.89
- AVG Volume (30 Days)
- JAZZ 1.3M
- QRVO 2.4M
- Earning Date
- JAZZ 05-06-2025
- QRVO 04-29-2025
- Dividend Yield
- JAZZ N/A
- QRVO N/A
- EPS Growth
- JAZZ 49.21
- QRVO N/A
- EPS
- JAZZ 7.51
- QRVO 0.58
- Revenue
- JAZZ $4,064,808,000.00
- QRVO $3,718,971,000.00
- Revenue This Year
- JAZZ $7.60
- QRVO $0.51
- Revenue Next Year
- JAZZ $3.47
- QRVO $5.78
- P/E Ratio
- JAZZ $13.00
- QRVO $124.78
- Revenue Growth
- JAZZ 5.76
- QRVO N/A
- 52 Week Low
- JAZZ $95.49
- QRVO $49.46
- 52 Week High
- JAZZ $148.06
- QRVO $130.99
- Technical
- Relative Strength Index (RSI)
- JAZZ 33.01
- QRVO 63.04
- Support Level
- JAZZ $97.50
- QRVO $69.03
- Resistance Level
- JAZZ $120.67
- QRVO $74.21
- Average True Range (ATR)
- JAZZ 4.33
- QRVO 2.38
- MACD
- JAZZ -0.53
- QRVO 1.45
- Stochastic Oscillator
- JAZZ 1.21
- QRVO 93.62
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About QRVO Qorvo Inc.
Qorvo represents the combined entity of RF Micro Devices and TriQuint Semiconductor, which merged in January 2015. The company specializes in radio frequency filters, power amplifiers, and front-end modules used in many of the world's most advanced smartphones. Qorvo also has a suite of products sold into a variety of nonsmartphone end markets, such as wireless base stations, cable TV and networking equipment, and infrastructure and military applications.